Klinisk Biokemi i Norden · 3 2018
| 23
19. Boschetti G, Laidet M, Moussata D, Stefanescu
C, Roblin X, Phelip G, et al. Levels of fecal
calprotectin are associated with the severity
of postoperative endoscopic recurrence in
asymptomatic patients with Crohn’s disease.
Am J Gastroenterol 2015; 110: 865–72.
20. Louis E, Mary JY, Vernier-Massouille G, Gri-
maud JC, Bouhnik Y, Laharie D, et al. Main-
tenance of remission among patients with
Crohn’s disease on antimetabolite therapy after
infliximab therapy is stopped. Gastroenterol-
ogy 2012;142:63–70
21. Karlsen TH, Folseraas T, Thorburn D, Vester-
hus M. Primary sclerosing cholangitis - a com-
prehensive review. J Hepatol 2017;67:1298-1323.
22. Voigtländer T, Wlecke J, Negm A, Lenzen H,
Manns M, Lankisch T. Calprotectin in bile: a
disease severity marker in patients with pri-
mary sclerosing cholangitis. J Clin Gastroen-
terol. 2014;48:866-9.
23. Gauss A, Sauer P, Stiehl A, Rupp C, Krisam J,
Leopold Y, et al. Evaluation of biliary calprotec-
tin as a biomarker in primary sclerosing chol-
angitis. Medicine (Baltimore). 2016;95:e3510.
24. Vesterhus M, Holm A, Hov J, Nygård S,
Schrumpf E, Melum E, et al. Novel serum and
bile protein markers predict primary scleros-
ing cholangitis disease severity and prognosis.
J Hepatol 2017;66:1214-22.
25. Färkkilä M, Arola J, Jokelainen K, Kolho K-L,
Hämäläinen E, Alfthan H. Bile duct inflam-
mation assessed by biliary calprotectin and
neutrophils correlates with risk of biliary dys-
plasia and cholangiocancer in PSC. UEG, 2016
OP 031.
26. Färkkilä M, Mustonen H, Jokelainen K, Arola
J, H. Alfthan H. Surrogate markers for disease
progression and risk for biliary neoplasia in
primary sclerosing cholangitis. UEG 2017.
OP287
27. Bae SC, Lee YH. Calprotectin levels in rheu-
matoid arthritis and their correlation with
disease activity: a meta-analysis. Postgrad Med.
2017;129:531-7.
28. Ometto F, Friso L, Astorri D, Botsios C,
Raffeiner B, Punzi L, Doria A. Calpro-
tectin in rheumatic diseases. Exp Biol Med
2017;242:859–73.
29. Inciarte-Mundo J, Ramirez J, Hernández MV,
Ruiz-Esquide V, Cuervo A, Cabrera-Villalba
SR, et al. Calprotectin and TNF trough
serum levels identify power Doppler ultra-
sound synovitis in rheumatoid arthritis and
psoriatic arthritis patients in remission or
with low disease activity. Arthritis Res Ther
2016;18:160.
30. Nordal HH, Brokstad KA, Solheim M, Halse
AK, Kvien TK, Hammer HB. Calprotectin
(S100A8/A9) has the strongest association with
ultrasound-detected synovitis and predicts
response to biologic treatment: results from
a longitudinal study of patients with estab-
lished rheumatoid arthritis. Arthritis Res Ther
2017;19:1-10.
31. Hammer HB1, Ødegård S, Syversen SW, Land-
ewé R, van der Heijde D, Uhlig T, et al. Calpro-
tectin (a major S100 leucocyte protein) predicts
10-year radiographic progression in patients
with rheumatoid arthritis. Ann Rheum Dis
2010;69:150-154.
32. Nordal HH, Brun JG, Hordvik M, Elddsheim
M, Jonsson R, Halse AK. Calprotectin (S100A8/
A9) and S100A12 are associated with measures
of disease activity in a longitudinal study of
patients with rheumatoid arthritis treated with
infliximab. Scand J Rheumatol 2016;45:274–81.
33. Choi IY, Gerlag DM, Herenius MJ, Thurlings
RM, Wijbrandts CA, Foell D, et al. MRP8/14
serum levels as a strong predictor of response
to biological treatments in patients with rheu-
matoid arthritis. Ann RheumDis 2015;74:499-
505.
34. Turina MC, Yeremenko N, Paramarta JE, De
Rycke L, Baeten D. Calprotectin (S100A8/9) as
serum biomarker for clinical response in proof-
of-concept trials in axial and peripheral spon-
dyloarthritis. Arthritis Res Ther 2014;16:413.
35. Wouthuyzen-Bakker M, Ploegmakers JJW,
Kampinga GA, Wagenmakers-Huizenga L;
Jutte PC, Muller Kobold AC. Synovial calpro-
tectin. Bone Joint J 2017;99-B:660–5.
36. Bello C, Roseth A, Guardiola J, Reenaers C,
Ruiz-Cerulla A, Van Kemseke C, et al. Usabil-
ity of a home-based test for the measurement
of fecal calprotectin in asymptomatic IBD
patients. Dig Liver Dis 2017;49: 991–6.
